Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2025 Mar;46(3):213-225.
doi: 10.15537/smj.2025.46.3.20240920.

Effects of antidiabetic drugs on the level of serum uric acid in patients who have type 2 diabetes

Gang Wang  1 , Guixia Wang  1
Affiliations
Review

Effects of antidiabetic drugs on the level of serum uric acid in patients who have type 2 diabetes

Gang Wang et al. Saudi Med J. 2025 Mar.

Abstract

Hyperuricemia and type 2 diabetes mellitus (T2DM) are interconnected, in that each disorder increases risk for the other. Some antidiabetic drugs may decrease the level of serum uric acid (SUA). This narrative review describes the effects of multiple antidiabetic drugs on the SUA level and their possible mechanisms of action in patients with T2DM. The results showed that sodium glucose contransporter-2 inhibitors (SGLT2is), thiazolidinediones, metformin, and linagliptin decreased the SUA; insulin, sitagliptin, and alogliptin increased the SUA; and glucagon-like peptide-1 receptor agonists (GLP-1 RAs), sulfonylureas, and alpha-glucosidase inhibitors had little effect on the SUA. Sodium glucose contransporter-2 inhibitors appeared to have the greatest effect on lowering SUA, possibly because they reduce pentose phosphate pathway metabolism and increase the renal excretion of urate by altering renal tubular uric acid transporters. Among all antidiabetic drugs currently used, SGTL2is appeared to be the most promising therapeutic option for T2DM patients with hyperuricemia.

Keywords: antidiabetic drugs; cardiovascular disease; hyperuricemia; serum uric acid; type 2 diabetes mellitus.

PubMed Disclaimer

Similar articles

See all similar articles

References

    1. Polito L, Bortolotti M, Battelli MG, Bolognesi A. Chronic kidney disease: which role for xanthine oxidoreductase activity and products? Pharmacol Res 2022; 184: 106407. - PubMed
    1. Lin S. Interpretation of Chinese guidelines for the diagnosis and treatment of hyperuricemia and gout (2019). J Clin Intern Med 2020; 37: 460-462.
    1. Leask MP, Merriman TR. The genetic basis of urate control and gout: insights into molecular pathogenesis from follow-up study of genome-wide association study loci. Best Pract Res Clin Rheumatol 2021; 35: 101721. - PubMed
    1. Boocock J, Leask M, Okada Y, Matsuo H, Kawamura Y, Shi Y, et al. . Genomic dissection of 43 serum urate-associated loci provides multiple insights into molecular mechanisms of urate control. Hum Mol Genet 2020; 29: 923-943. - PubMed
    1. Reynolds RJ, Irvin MR, Bridges SL, Kim H, Merriman TR, Arnett DK, et al. . Genetic correlations between traits associated with hyperuricemia, gout, and comorbidities. Eur J Hum Genet 2021; 29: 1438-1445. - PMC - PubMed

MeSH terms

LinkOut - more resources